EyePoint Pharmaceuticals Inc (EYPT)
11.84
-0.68
(-5.43%)
USD |
NASDAQ |
May 17, 16:00
11.83
-0.01
(-0.08%)
After-Hours: 20:00
EyePoint Pharmaceuticals Enterprise Value: 317.33M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 317.33M |
| May 16, 2024 | 352.75M |
| May 15, 2024 | 374.62M |
| May 14, 2024 | 349.10M |
| May 13, 2024 | 337.12M |
| May 10, 2024 | 330.35M |
| May 09, 2024 | 360.56M |
| May 08, 2024 | 302.75M |
| May 07, 2024 | 318.89M |
| May 06, 2024 | 284.00M |
| May 03, 2024 | 728.80M |
| May 02, 2024 | 739.21M |
| May 01, 2024 | 640.25M |
| April 30, 2024 | 617.33M |
| April 29, 2024 | 618.89M |
| April 26, 2024 | 573.06M |
| April 25, 2024 | 542.33M |
| April 24, 2024 | 558.48M |
| April 23, 2024 | 615.77M |
| April 22, 2024 | 546.21M |
| April 19, 2024 | 581.13M |
| April 18, 2024 | 573.65M |
| April 17, 2024 | 745.26M |
| April 16, 2024 | 790.16M |
| April 15, 2024 | 762.22M |
| Date | Value |
|---|---|
| April 12, 2024 | 820.59M |
| April 11, 2024 | 842.54M |
| April 10, 2024 | 783.67M |
| April 09, 2024 | 774.69M |
| April 08, 2024 | 734.78M |
| April 05, 2024 | 712.33M |
| April 04, 2024 | 705.85M |
| April 03, 2024 | 735.78M |
| April 02, 2024 | 712.33M |
| April 01, 2024 | 711.84M |
| March 31, 2024 | 731.79M |
| March 28, 2024 | 698.95M |
| March 27, 2024 | 705.93M |
| March 26, 2024 | 696.96M |
| March 25, 2024 | 749.78M |
| March 22, 2024 | 778.18M |
| March 21, 2024 | 835.99M |
| March 20, 2024 | 832.50M |
| March 19, 2024 | 770.21M |
| March 18, 2024 | 730.35M |
| March 15, 2024 | 739.32M |
| March 14, 2024 | 752.27M |
| March 13, 2024 | 769.71M |
| March 12, 2024 | 805.59M |
| March 11, 2024 | 808.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-36.76M
Minimum
Dec 19 2022
1.126B
Maximum
Feb 12 2024
222.38M
Average
164.12M
Median
Enterprise Value Benchmarks
| Nanoviricides Inc | 21.13M |
| Bio-Path Holdings Inc | 0.4006M |
| GlycoMimetics Inc | -11.98M |
| Ocular Therapeutix Inc | 539.23M |
| Aileron Therapeutics Inc | 62.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -29.28M |
| Revenue (Quarterly) | 11.68M |
| Total Expenses (Quarterly) | 45.00M |
| EPS Diluted (Quarterly) | -0.55 |
| Gross Profit Margin (Quarterly) | 93.50% |
| Profit Margin (Quarterly) | -250.6% |
| Earnings Yield | -15.29% |
| Normalized Earnings Yield | -14.98 |